Loading...
•
Sep 30, 2024
Supernus Q3 2024 Earnings Report
Reported strong financial results driven by Qelbree and GOCOVRI sales growth and raised full-year 2024 guidance for total revenues and operating earnings.
Key Takeaways
Supernus Pharmaceuticals reported a 14% increase in total revenue for Q3 2024, driven by strong sales of Qelbree and GOCOVRI. Operating earnings significantly improved compared to the same period in the previous year. The company also announced positive topline data from its Phase 2a study of SPN-820 in major depressive disorder and initiated a Phase 1 study for SPN-443.
Qelbree net sales increased by 68% compared to Q3 2023.
GOCOVRI net sales increased by 8% compared to Q3 2023.
Total revenues increased by 14% compared to Q3 2023.
Operating earnings improved significantly, reaching $40.9 million compared to $8.1 million in Q3 2023.
Revenue by Segment
Forward Guidance
Supernus Pharmaceuticals is increasing its full year 2024 financial guidance for total revenues and operating earnings (GAAP and Non-GAAP).
Positive Outlook
- Total revenues are projected to be between $630 million and $650 million.
- Combined R&D and SG&A expenses are expected to be between $430 million and $450 million.
- Operating earnings are projected to be between $50 million and $65 million.
- Adjusted operating earnings are projected to be between $150 million and $170 million.
- The guidance reflects continued generic erosion of Trokendi XR and generic erosion of Oxtellar XR beginning in September 2024.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...